IL2 and renal cell carcinoma: Table 5 summarizes some representative early-phase vaccine trials in RCC. A notable phase II study (NCT00031564) evaluated a B7-1 gene-modified autologous tumor cell vaccine combined with interleukin-2 (IL-2) in stage IV RCC [102].